Global GastroparesisMarket
The global Gastroparesis market is estimated to be worth over USD11,895.83 Mn in 2033 and is expected to grow at CAGR of3.6% during the forecast period (2024-2033).
The global gastroparesis market is witnessing notable dynamics led by a confluence of factors, developments, and innovative technologies focused at addressing the challenges posed by this chronic gastrointestinal disorder. Significant driving factors comprise the growing prevalence of gastroparesis, specifically among individuals with diabetes and those undergoing abdominal surgeries, paving its way to a soaring patient population in necessity of effective management and treatment strategies. Substantial developments in the market compriseinnovations in diagnostic tools, such as gastric emptying scintigraphyand wireless motility capsules, facilitating more accurate diagnosis and monitoring of gastroparesis. In addition to that, emerging therapies targeting novel mechanisms of action, comprising gastric neuromodulation and ghrelin receptor agonists, providehope for enhancing symptoms and gastric motility, potentially revolutionizing the treatment panorama for gastroparesis. Alongside, the consolidation of digital health technologies, comprising mobile applications for symptom tracking and telemedicine platforms for remote patient monitoring, is transforming patient care and improving treatment adherence.
Major novel technologies in the global gastroparesis market are fueling advancements in diagnosis, treatment, and patient management. Wireless motility capsules provide a minimally invasive approach to evaluate gastric motility and transit time, offering valuable insights into gastrointestinal function. Gastric neuromodulation devices, such as gastric electrical stimulators, provide targeted stimulation to the stomach muscles or nerves, modulating gastric contractions and enhancing gastric emptying in refractory cases of gastroparesis. Ghrelin receptor agonists represent a novel pharmacological approach to improve gastric motility by targeting ghrelin receptors, which hold a leading role in regulating gastrointestinal motility and appetite. In addition to that, digital health technologies are revolutionizing the delivery of care for gastroparesis patients, allowing remote monitoring of symptoms, medication adherence, and dietary intake, while supporting communication between patients and healthcare providers.
Overall, the global gastroparesis market presents notable opportunities for stakeholders to invest in research, innovation, and collaborative partnerships emphasized at addressing the multifaceted challenges of this intricate gastrointestinal disorder. By leveraging advancements in technology and therapeutic innovation, the market can drive progress towards more effective treatments, enhanced diagnostic tools, and improved care delivery models, ultimately enhancing outcomes and quality of life for individuals affected by gastroparesis.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, Gastroparesismarket, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Gastroparesismarket, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall Gastroparesismarket, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the Gastroparesismarket and its likely evolution in the mid-to-long term.
A brief introduction to the Gastroparesis, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Gastroparesis.
A detailed assessment of the market landscape of Gastroparesisthat are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Type (Idiopathic, Diabetic, Post- Surgical, Others), By Drug Class (Prokinetic Drugs, Antiemetics, Botulinum Toxin Injection, Antidepressants, Others), By Treatment (Jejunostomy, Gastric Electric Stimulation, Parenteral Nutrition, Diabetic Gastroparesis, Chronic Gastroparesis, Idiopathic Gastroparesis, Post-Operative Gastroparesis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various Gastroparesisdevelopers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various Gastroparesisfocused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the Gastroparesisover the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the Gastroparesismarket over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Type (Idiopathic, Diabetic, Post- Surgical, Others), By Drug Class (Prokinetic Drugs, Antiemetics, Botulinum Toxin Injection, Antidepressants, Others), By Treatment (Jejunostomy, Gastric Electric Stimulation, Parenteral Nutrition, Diabetic Gastroparesis, Chronic Gastroparesis, Idiopathic Gastroparesis, Post-Operative Gastroparesis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.